MARKET NEWS

Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 in Combination with KEYTRUDAr as First-line Treatment for HPV+ Recurrent/Metastatic Head & Neck Cancer
OliX Pharmaceuticals Launches New Subsidiary to Develop mRNA Vaccines & Therapeutics
Melt Pharmaceuticals Completes Phase 1 Study for Sublingual, Non-Opioid Pain & Sedation Drug Candidate
uniQure Announces Positive Recommendation From Data Safety Monitoring Board of Phase 1/2 Clinical Trial
Hyloris & Purna Female Healthcare Announce Development Partnership
Emerald Health Pharmaceuticals Demonstrates Potential Disease-Modifying Activity of Novel Product Candidate With Multi-Modal Mechanism of Action in Parkinson’s Disease
Trizell Signs Development & Manufacturing Agreement With Catalent for Macrophage-Based Advanced Cell Therapy

  FEATURED EDITORIAL

  COMPANY PROFILE

Partnering with Alcami connects you to a team of highly intelligent-problem solvers that can advance your product through every stage of the development lifecycle. With over 300,000ft² in the US, our team of 700 professionals across four US scientific campuses serves biologics and pharmaceutical companies of all sizes. Leveraging over 40 years of experience, Alcami provides customizable and innovative solutions for formulation development, analytical development and testing services, clinical and commercial finished dosage form manufacturing (oral solid dose and parenteral), packaging, and stability services. Whether you are a virtual start-up or a large organization, we can help you deliver breakthrough therapies to patients faster. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Samsung Biologics, National OncoVenture & Eutilex Obtains IND Approval From FDA

Samsung Biologics, National OncoVenture & Eutilex Obtains IND Approval From FDA

Samsung Biologics recently announced another successful Investigational New Drug (IND) clearance from the FDA for its client to begin clinical trials on a cancer immunotherapy, furthering the….

Maravai LifeSciences Expands Its Intellectual Property Portfolio

Maravai LifeSciences Expands Its Intellectual Property Portfolio

Maravai LifeSciences, Inc. recently announced the United States Patent and Trademark Office has issued a new patent, United States Patent No. 10,913,768, to the company’s TriLink Biotechnologies subsidiary…..

Quotient Sciences Acquires UK-Based Contract Development & Manufacturing Organization

Quotient Sciences Acquires UK-Based Contract Development & Manufacturing Organization

Quotient Sciences, the drug development and manufacturing accelerator, recently announced it has acquired Arcinova, the UK-based multiservice contract development and….

Celon Pharma Announces Successful Completion of Phase 1A Trial of CPL’116, JAK-ROCK Inhibitor

Celon Pharma Announces Successful Completion of Phase 1A Trial of CPL’116, JAK-ROCK Inhibitor

Celon Pharma S.A. recently announced the successful completion of its Phase 1A trial of its JAK/ROCK kinases dual inhibitor, CPL’116. CPL’116 was administered orally in….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

February 24 – ODT/Fast Dissolve
March 3 – Transdermal/Topical Delivery